登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
SBRT Versus Surgical Resection for Small HCC
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07381660,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
For patients with recurrent disease, recurrence must occur at least 1 year after prior curative treatments;
入选标准第 6 条
Previously treated patients must not have received systemic therapy within 6 months before enrollment;
入选标准第 7 条
A normal liver volume of ≥700 cc, with an estimated future liver remnant volume of >40% after resection;
入选标准第 9 条
A Karnofsky performance-status score of ≥90;
入选标准第 10 条
In previously treated patients, tumor size must be assessed according to RECIST version 1.1 at enrollment;
入选标准第 8 条
Pregnancy or breastfeeding;
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07381660,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 18 to 75 years, with no restriction on sex; Clinically or pathologically diagnosed hepatocellular carcinoma, according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 edition); A solitary tumor with a maximum diameter of ≤5 cm, for which treatment is indicated; No radiologic evidence of macrovascular invasion, distant metastasis, or lymph node metastasis; Treatment-naïve or previously treated patients are eligible, provided that they are deemed suitable for both surgical resection and radiotherapy by a multidisciplinary team (MDT) and do not require concomitant systemic therapy at enrollment; For patients with recurrent disease, recurrence must occur at least 1 year after prior curative treatments; Previously treated patients must not have received systemic therapy within 6 months before enrollment; In previously treated patients, tumor size must be assessed according to RECIST version 1.1 at enrollment; A normal liver volume of ≥700 cc, with an estimated future liver remnant volume of >40% after resection; A Karnofsky performance-status score of ≥90; Child-Pugh class A liver function; An estimated life expectancy of more than 6 months; Adequate organ function, defined as follows: white-cell count ≥3.5×10⁹/L, absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥75.0×10⁹/L, hemoglobin ≥90 g/L; serum albumin ≥28 g/L; total bilirubin ≤1.5 times the upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase ≤2.5 times the ULN; serum creatinine ≤1.5 times the ULN or creatinine clearance >60 mL per minute; and no severe concomitant organic disease; The ability to understand the study procedures and to provide written informed consent before the initiation of any study-specific procedures, with agreement to receive treatment and follow-up according to the study protocol.排除标准:Exclusion Criteria:
Severe dysfunction of major organs, including the heart, lungs, or kidneys; active infection other than viral hepatitis; or other serious concomitant conditions that preclude tolerance of either surgery or radiotherapy; Contraindications to surgical resection or radiotherapy; A history of other malignant tumors, with the exception of nonmelanoma skin cancer, carcinoma in situ of the cervix, or previously cured prostate cancer, nasopharyngeal carcinoma, breast cancer, or early-stage laryngeal cancer; A history of multiple abdominal surgeries or liver or other solid-organ transplantation; Previous radiotherapy to the upper abdomen; Pregnancy or breastfeeding; Any other condition that may interfere with patient enrollment or the assessment of study outcomes; Refusal to comply with the follow-up requirements of the study protocol or refusal to provide written informed consent.
引自 ClinicalTrials.gov, NCT07381660, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07381660,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。